Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Юношеский артрит с системным началом

Список литературы

  1. Textbook of Pediatric Rheumatology. Elsevier 2016. doi:10.1016/C2012-0-00349-3
  2. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev 2016;15:931–4. doi:10.1016/j.autrev.2016.07.004
  3. Janow G, Schanberg LE, Setoguchi S, et al. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. J Rheumatol 2016;43:1755–62. doi:10.3899/jrheum.150997
  4. Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929–36. doi:10.1002/acr.20497
  5. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465–82. doi:10.1002/acr.20460
  6. Баранов А.А, Алексеева Е.И, editors. Ревматические болезни у детей. Москва: : ПедиатрЪ 2016.
  7. Alexeeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Curr Pediatr 2015;14:78–94. doi:10.15690/vsp.v14i1.1266
  8. Баранов АА, Алексеева ЕИ, Бзарова ТМ, et al. Протокол ведения пациентов с ювенильным артритом. Вопросы Современной Педиатрии 2013;12:37–56.
  9. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012;12:56–9. doi:10.1016/j.autrev.2012.07.022
  10. Marzan KAB, Shaham B. Early juvenile idiopathic arthritis. Rheum Dis Clin North Am 2012;38:355–72. doi:10.1016/j.rdc.2012.04.006
  11. Shenoi S, Wallace CA. Diagnosis and Treatment of Systemic Juvenile Idiopathic Arthritis. J Pediatr 2016;177:19–26. doi:10.1016/j.jpeds.2016.06.056
  12. Тепаев РФ. Синдром диссеминированного внутрисосудистого свертывания у детей. Диагностика и лечение. Педиатрическая Фармакология 2010;7:27–31.
  13. De Vere-Tyndall A, Macauley D, Ansell BM. Disseminated intravascular coagulation complicating systemic juvenile chronic arthritis ("Still's disease"). Clin Rheumatol 1983;2:415–8. doi:10.1007/BF02041564
  14. Oren H, Cingöz I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: clinical and laboratory features and prognostic factors influencing the survival. Pediatr Hematol Oncol 2005;22:679–88. doi:10.1080/08880010500278749
  15. Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. Arch Dis Child 2017; 102:187–93. doi:10.1136/archdischild-2016-311053
  16. Scott JP, Gerber P, Maryjowski MC, et al. Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis. Arthritis Rheum 1985;28:256–61. doi:10.1002/art.1780280304
  17. Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis 2018;77:1558–65. doi:10.1136/annrheumdis-2017-212515
  18. Howell MD, Davis AM. Management of Sepsis and Septic Shock. JAMA 2017;317:847. doi:10.1001/jama.2017.0131
  19. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med 2020;46:10–67. doi:10.1007/s00134-019-05878-6
  20. Yokoyama T, Shimizu M, Ikeno I, et al. [Case of systemic-onset juvenile idiopathic arthritis complicated with sepsis --usefulness of cytokine profile for the differentiation between macrophage activation syndrome and sepsis]. Nihon Rinsho Meneki Gakkai Kaishi 2011;34:105–11. doi:10.2177/jsci.34.105
  21. Щербина АЮ. Первичные иммунодефициты -реалии XXI века. Вопросы Гематологиионкологии И Иммунопатологии В Педиатрии. 2016;15:8-9–9. doi:10.24287/1726-1708-2016-15-1-8-9
  22. Аксенова ВА, Барышников ЛА, Клевно НИ, et al. Новые возможности скрининга и диагностики различных проявлений туберкулезной инфекции у детей и подростков в России. Вопросы Современной Педиатрии. 2011;10:16–22.https://vsp.spr-journal.ru/jour/article/view/638 (accessed 14 Apr 2020).
  23. Barut K, Şahin S, Adrovic A, et al. Tuberculin skin test response in patients with juvenile idiopathic arthritis on anti-TNF therapy. Turk J Med Sci 2018;48:1109–14. doi:10.3906/sag-1710-190
  24. Brunelli JB, Bonfiglioli KR, Silva CA, et al. Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country. Rev Bras Reumatol 2017;57:392–6. doi:10.1016/j.rbre.2016.11.004
  25. García-Basteiro AL, DiNardo A, Saavedra B, et al. Point of care diagnostics for tuberculosis. Pulmonology 2018;24:73–85. doi:10.1016/j.rppnen.2017.12.002
  26. Hsin Y-C, Zhuang L-Z, Yeh K-W, et al. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan. PloS One 2015;10:e0128768. doi:10.1371/journal.pone.0128768
  27. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res 2013;65:1551–63. doi:10.1002/acr.22087
  28. Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev 2014;13:546–9. doi:10.1016/j.autrev.2014.01.005
  29. Sood SK. Lyme disease in children. Infect Dis Clin North Am 2015;29:281–94. doi:10.1016/j.idc.2015.02.011
  30. Giancane G, Swart JF, Castagnola E, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther 2020;22:71. doi:10.1186/s13075-020-02167-2
  31. Vassilopoulos D. Rheumatic manifestations of acute & chronic viral arthritis. In: Stone J, Imboden J, Hellmann D, eds. Current Diagnosis & Treatment in Rheumatology. New York: : McGraw-Hill 2013. https://www.overdrive.com/search?q=AD0C2D1C-E2C0-4722-AD4B-D76EBA123511 (accessed 13 May 2020).
  32. McAuley JB. Toxoplasmosis in Children: Pediatr Infect Dis J 2008;27:161–2. doi:10.1097/INF.0b013e3181658abb
  33. Ferrara G, Pastore S, Sancin L, et al. Fecal Calprotectin to Detect Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis. J Rheumatol 2018;45:1418–21. doi:10.3899/jrheum.171200
  34. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179–207. doi:10.1016/j.crohns.2014.04.005
  35. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257–91. doi:10.1097/MPG.0000000000002035
  36. Koca B, Sahin S, Adrovic A, et al. Cardiac involvement in juvenile idiopathic arthritis. Rheumatol Int 2017;37:137–42. doi:10.1007/s00296-016-3534-z
  37. Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev 2018;39:444–53. doi:10.1542/pir.2017-0268
  38. Zucker EJ, Lee EY, Restrepo R, et al. Hip disorders in children. AJR Am J Roentgenol 2013;201:W776-796. doi:10.2214/AJR.13.10623
  39. Munir S, Patil K, Miller E, et al. Juvenile idiopathic arthritis of the axial joints: a systematic review of the diagnostic accuracy and predictive value of conventional MRI. AJR Am J Roentgenol 2014;202:199– 210. doi:10.2214/AJR.12.10475
  40. Dumaine C, Bekkar S, Belot A, et al. Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte. Joint Bone Spine 2020;87:49–55. doi:10.1016/j.jbspin.2019.07.011
  41. Sierra D, Wood M, Kolli S, et al. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev 2018;39:542–9. doi:10.1542/pir.2017-0234
  42. Hynes L, Saetes S, McGuire B, et al. Child and Family Adaptation to Juvenile Idiopathic Arthritis— A Systematic Review of the Role of Resilience Resources and Mechanisms. Front Psychol 2019;10:2445. doi:10.3389/fpsyg.2019.02445
  43. Yokota S, Itoh Y, Morio T, et al. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab. J Rheumatol 2015;42:712–22. doi:10.3899/jrheum.140288
  44. Ravelli A, Davì S, Minoia F, et al. Macrophage Activation Syndrome. Hematol Oncol Clin North Am 2015;29:927–41. doi:10.1016/j.hoc.2015.06.010
  45. Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 2016;75:481–9. doi:10.1136/annrheumdis-2015-208982
  46. Schulert GS, Minoia F, Bohnsack J, et al. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res 2018;70:409–19. doi:10.1002/acr.23277
  47. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991–1003. doi:10.1097/MPG.0000000000001594
  48. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol Hoboken NJ 2017;69:1521–37. doi:10.1002/art.40137
  49. Galindo-Zavala R, Bou-Torrent R, Magallares-López B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J2020;18:20. doi:10.1186/s12969-020-0411 -9
  50. Zulian F, Martini G, Gobber D, et al. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatol Oxf Engl 2003;42:1254– 9. doi:10.1093/rheumatology/keg358
  51. Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J2018;16:46. doi:10.1186/s12969-018-0255-8
  52. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849–57. doi:10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F
  53. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191–201. doi:10.1002/art.20288
  54. Hunt PG, Rose CD, McIlvain-Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 1997;24:2230–2.
  55. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515–24. doi:10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7
  56. Alcantara AC de C, Leite CAC, Leite ACRM, et al. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis. J Rheumatol 2014;41:338–44. doi:10.3899/jrheum.130294
  57. Jahan A, Dewan V, Yadav TP. Leflunomide in systemic onset Juvenile idiopathic arthritis. Indian Pediatr 2012;49:750–2. doi:10.1007/s13312-012-0139-9
  58. Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2005;52: 554–62. doi:10.1002/art.20861
  59. Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther 2017;8:125–35. doi:10.2147/AHMT.S109495
  60. Harris JG, Kessler EA, Verbsky JW. Update on the treatment of juvenile idiopathic arthritis. Curr Allergy Asthma Rep 2013; 13:337–46. doi:10.1007/s11882-013-0351-2
  61. Kimura Y, Beukelman T, Morgan-DeWitt E, et al. Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study. In: ACR Meeting Abstracts. San Francisco, CA: 2015. https://acrabstracts.org/abstract/results-from-the-childhood-arthritis-and-rheumatology-research-alliance-systemic-jia-consensus-treatment-plans-pilot-study/ (accessed 14 Mar 2020).
  62. Mitchell E, Jones G. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2016;12:103–14. doi:10.1586/1744666X.2016.1127159
  63. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol Hoboken NJ 2014;66:1405–13. doi:10.1002/art.38615
  64. Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018;77:819–28. doi:10.1136/annrheumdis-2018-213030
  65. Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatol Oxf Engl 2016;55:669–79. doi:10.1093/rheumatology/kev382
  66. Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 2016;75:1654–60. doi:10.1136/annrheumdis-2015-207818
  67. Arthur VL, Shuldiner E, Remmers EF, et al. IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol Hoboken NJ 2018;70:1319–30. doi:10.1002/art.40498
  68. Grom AA, Ilowite NT, Pascual V, et al. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis Rheumatol Hoboken NJ 2016;68:218–28. doi:10.1002/art.39407
  69. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1163–72. doi:10.1007/s 10067-011-1720-7
  70. Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin RheumatolPract Rep Rheum Musculoskelet Dis 2009;15:363–5. doi:10.1097/RHU.0b013e3181ba3c6f
  71. Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol 2019;10:1990. doi:10.3389/fimmu.2019.01990
  72. Kearsley-Fleet L, Sampath S, McCann LJ, et al. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. Rheumatol Oxf Engl 2019; 58:331–5. doi:10.1093/rheumatology/key306
  73. Narvaez J, Díaz-Torné C, Juanola X, et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:607–8. doi:10.1136/ard.2008.092106
  74. Siberry GK, Abzug MJ, Nachman S, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J 2013;32:i. doi:10.1097/01.inf.0000437856.09540.11
  75. Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052–9. doi:10.4065/82.9.1052
  76. Sulieman SE, Metjian TA, Zaoutis TE, et al. Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. Curr Fungal Infect Rep 2014;8:45– 55. doi:10.1007/s12281-014-0177-y
  77. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 2018;77:21–9. doi:10.1136/annrheumdis-2016-210456
  78. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763–9. doi:10.1056/NEJM200003163421103
  79. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl JMed 2008;359:810–20. doi:10.1056/NEJMoa0706290
  80. Otten MH, Anink J, Spronk S, et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 2013;72:1806–12. doi:10.1136/annrheumdis-2012-201991
  81. PRO-KIND SJIA proj ect collaborators, Hinze CH, Holzinger D, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol 2018;16:7. doi:10.1186/s12969-018-0224-2
  82. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs Clin Immunother Biopharm Gene Ther 2017;31:299–316. doi:10.1007/s40259-017-0231 -8
  83. Takken T, Van Brussel M, Engelbert RHH, et al. Exercise therapy in juvenile idiopathic arthritis. Cochrane Database Syst Rev Published Online First: 23 April 2008. doi:10.1002/14651858.CD005954.pub2
  84. Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 2010;37:1763–7. doi:10.3899/jrheum.090874
  85. Pneumonia in Immunocompromised Patients: Overview, Causes of Pneumonia, HIV/AIDS. Published Online First: 23 March 2020.https://emedicine.medscape.com/article/807846-overview#a11.. (accessed 14 Apr 2020).
  86. Abe Y, Fujibayashi K, Nishizaki Y, et al. Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial. Acta Med Okayama 2019;73:85–9. doi:10.18926/AMO/56464
  87. Ghembaza A, Vautier M, Cacoub P, et al. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases. Chest 2020;158:2323–32. doi:10.1016/j.chest.2020.05.558
  88. Jiang X, Mei X, Feng D, et al. Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PloS One 2015;10:e0122171. doi:10.1371/journal.pone.0122171
  89. Kitazawa T, Seo K, Yoshino Y, et al. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother Off J Jpn Soc Chemother 2019;25:351–4. doi:10.1016/j.jiac.2019.01.005
  90. Park JW, Curtis JR, Kim MJ, et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther 2019;21:207. doi:10.1186/s13075-019-1996-6
  91. What's New Adult and Adolescent Opportunistic Infection. AIDSinfo. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/392/whats-new (accessed 14 Apr 2020).
  92. Aeschlimann FA, Chong S-L, Lyons TW, et al. Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses. J Pediatr 2019;204:162-171.e3. doi:10.1016/j.jpeds.2018.08.065
  93. de Camargo MC, Barros BCA, Fulone I, et al. Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. Front Pharmacol 2019;10:965. doi:10.3389/fphar.2019.00965
  94. Diener C, Horneff G. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review. Expert Opin Drug Saf 2019;18:719–32. doi:10.1080/14740338.2019.1632288
  95. Koç R, Sönmez HE, Çakan M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatol Int Published Online First: 21 December 2019. doi:10.1007/s00296-019-04498-z
  96. Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 2012;108:123–4. doi:10.1016/j.anai.2011.11.004
  97. Barut K, Yücel G, Sinoplu AB, et al. Evaluation of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: single center experience over a one-year period. Turk Pediatri Arsivi 2015;50:206–10. doi:10.5152/TurkPediatriArs.2015.3299
  98. Boom V, Anton J, Lahdenne P, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015;13:55. doi:10.1186/s12969-015-0055-3
  99. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465–77. doi:10.1182/blood.2018894618
  100. Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol Hoboken NJ 2014;66:3160–9. doi:10.1002/art.38802
  101. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016; 12:259–68. doi:10.1038/nrrheum.2015.179
  102. Aizawa-Yashiro T, Oki E, Tsuruga K, et al. Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy. Rheumatol Int 2012;32:1359–61. doi:10.1007/s00296-010-1413-6
  103. Georgiadou S, Gatselis NK, Stefos A, et al. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions. World J Clin Cases 2019;7:3394–406. doi:10.12998/wjcc.v7.i21.3394
  104. Roifman CM. Use of intravenous immune globulin in the therapy of children with rheumatological diseases. J Clin Immunol 1995;15:42S-51S. doi:10.1007/bf01540893
  105. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care 2014;2:15. doi:10.1186/2052-0492-2-15
  106. Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care Lond Engl 2012;16:R52. doi:10.1186/cc11256
  107. Henter J-I, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31. doi:10.1002/pbc.21039
  108. Chausset A, Gominon A-L, Montmaneix N, et al. Why we need a process on breaking news of Juvenile Idiopathic Arthritis: a mixed methods study. Pediatr Rheumatol Online J 2016;14:31. doi:10.1186/s12969-016-0092-6
  109. Scott C, Chan M, Slamang W, et al. Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. Clin Rheumatol 2019;38:563–75. doi:10.1007/s 10067-018-4304-y
  110. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:39–52. doi:10.1136/annrheumdis-2019-215882
  111. Alexeeva EI, Soloshenko MA, Dvoryakovskaya TM, et al. Efficacy and Safety of Immunization With Pneumococcal Polysaccharide Vaccine in Children With Juvenile Idiopathic Arthritis: Preliminary Results of a Prospective Open-Label Study. Curr Pediatr 2017;16:142–7. doi:10.15690/vsp.v16i2.1715
  112. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 2013;72:1362–6. doi:10.1136/annrheumdis-2012-202658
  113. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am 2008;28:833–49, ix. doi:10.1016/j.iac.2008.07.001
  114. Adesoye A, Nwachukwu L, Adigun M, et al. Varicella-Zoster Virus Infection in Children and Adolescents. US Pharm 2014;39:39–43.
  115. Adler SP, Marshall B. Cytomegalovirus infections. Pediatr Rev 2007;28:92–100. doi:10.1542/pir.28-3-92
  116. Whyte LA, Al-Araji RA, McLoughlin LM. Guidelines for the management of acute gastroenteritis in children in Europe. Arch Dis Child Educ Pract Ed 2015;100:308–12. doi:10.1136/archdischild-2014-307253
  117. Thornton J, Ashcroft D, O'Neill T, et al. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol Assess Winch Engl 2008;12:iii–ix, xi–xiv, 1–208.
  118. Zhang Y, Milojevic D. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations. Paediatr Drugs 2017;19:193–211. doi:10.1007/s40272-017-0219-3

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*